With de­layed re­view date loom­ing, Bris­tol My­ers un­corks more win­ning da­ta for block­buster-po­ten­tial heart drug

Bris­tol My­ers Squibb doled out a whop­ping $13 bil­lion for MyoKar­dia back in late 2020, main­ly on the block­buster hopes of heart drug mava­camten …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.